Latest Breaking News On - Garnier co victor floch paris - Page 2 : comparemela.com

Nicox Appoints Robert N Weinreb, M D and Sanjay G Asrani, M D to its Glaucoma Clinical Advisory Board

Nicox Appoints Robert N Weinreb, M D and Sanjay G Asrani, M D to its Glaucoma Clinical Advisory Board
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew yorkProvence alpes côd azurFrance generalNorth carolinaUnited kingdomReading centerHamilton centerDuke universityGavin spencerSanjay asraniMorris gleichRobertd fechtnerKepler cheuvreux damien choplainPharma bioDonaldl budenz

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux July 6, 2021 - release at 7:30 am CET Sophia Antipolis, France Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021: - 218,919 shares - Number of executions on sell side on semester: 1,298 - Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01 - Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37 As a reminder : • the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account: - 147,145 shares - Number of executions on sell side on semester: 609

New yorkUnited statesProvence alpes côd azurFrance generalUnited kingdomGavin spencerPharma bioKepler cheuvreux damien choplainMary ann changSophia antipolisSophie baumontCantor fitzgerald louise chenKepler cheuvreuxStates europeGarnier co victor floch parisHead of corporate development

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial July 2nd, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021. Mississippi trial Phase 2 at Nicox, amount used to guide the future development of NCX 4251 . We will announce the next steps in the development of NCX 4251 following an End-of-Phase 2 meeting with the FDA.

New yorkUnited statesProvence alpes côd azurFrance generalUnited kingdomGavin spencerPharma bioKepler cheuvreux damien choplainMary ann changSophia antipolisSophie baumontCantor fitzgerald louise chenStates europeGarnier co victor floch parisHead of corporate developmentLifesci advisors

Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico

Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico TM to Mexico Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATE TM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico. Grin is a Mexican specialty pharmaceutical company engaged in the development, manufacturing and commercialization of branded ophthalmic products. Gavin Spencer, With this licensing deal we welcome the first Latin showing the in new entrants in the allergic conjunctivitis space. Laboratorios Grin are

New yorkUnited statesProvence alpes côd azurFrance generalUnited kingdomSouth africaSouth koreaGavin spencerLuis guillermo cortPharma bioKepler cheuvreux damien choplainMary ann changSophia antipolisSophie baumontCantor fitzgerald louise chenAsia pacific

U S Patent Office Issues Notice of Allowance for Nicox s Latanoprostene Bunod in Normal Tension Glaucoma

U.S. Patent Office Issues Notice of Allowance for Nicox s Latanoprostene Bunod in Normal Tension Glaucoma April 27, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA , for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

New yorkUnited statesProvence alpes côd azurHong kongFrance generalUnited kingdomSouth koreaGavin spencerNicox latanoprostene bunodPharma bioKepler cheuvreux damien choplainMary ann changSophia antipolisSophie baumontCantor fitzgerald louise chenStates europe